Maxim Group initiated coverage on NexGel with a new price target
$NXGL
Medical/Dental Instruments
Health Care
Maxim Group initiated coverage of NexGel with a rating of Buy and set a new price target of $6.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/25/2022 | $6.00 | Buy | Maxim Group |
Maxim Group initiated coverage of NexGel with a rating of Buy and set a new price target of $6.00
4 - NEXGEL, INC. (0001468929) (Issuer)
4 - NEXGEL, INC. (0001468929) (Issuer)
4 - NEXGEL, INC. (0001468929) (Issuer)
3 - NEXGEL, INC. (0001468929) (Issuer)
4 - NEXGEL, INC. (0001468929) (Issuer)
4 - NEXGEL, INC. (0001468929) (Issuer)
Second quarter 2025 revenue totaled $2.88 million, an increase of 100.3% as compared to $1.44 million for the same period year-over-year Gross Profit for the quarter was 43.6%, compared to 20.3% for the same period in 2024 Company is reiterating revenue guidance for 2025 of $13 million and to achieve positive EBITDA during the year LANGHORNE, Pa., Aug. 12, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced its second quarter 2025 financial results for the perio
Management will host a conference call at 4:30 P.M. ET on the same day LANGHORNE, Pa., Aug. 06, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced it will report its financial results for the second quarter 2025, after the market close on August 12, 2025. Following the release of its financial results, the Company will host a conference call at 4:30 P.M. ET on the same day. Second Quarter 2025 Financial Results Conference CallDate: August 12, 2025Time: 4:30 P.M. ETLive Call: 1-800-274-8461 (U.S. Toll Free) or 1-203-518-9814 (I
LANGHORNE, Pa., Aug. 05, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced the appointment of Steve Ciardiello, CPA, to its Board of Directors. With more than 25 years of experience as a senior finance executive and current Chief Accounting Officer of Shutterstock, Inc. (NYSE:SSTK), Mr. Ciardiello has a proven track record of financial leadership, strategic execution, and corporate governance in high-growth, publicly traded companies. "Steve's extensive experience, financial leader
10-Q - NEXGEL, INC. (0001468929) (Filer)
8-K - NEXGEL, INC. (0001468929) (Filer)
8-K - NEXGEL, INC. (0001468929) (Filer)
Second quarter 2025 revenue totaled $2.88 million, an increase of 100.3% as compared to $1.44 million for the same period year-over-year Gross Profit for the quarter was 43.6%, compared to 20.3% for the same period in 2024 Company is reiterating revenue guidance for 2025 of $13 million and to achieve positive EBITDA during the year LANGHORNE, Pa., Aug. 12, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced its second quarter 2025 financial results for the perio
Management will host a conference call at 4:30 P.M. ET on the same day LANGHORNE, Pa., Aug. 06, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced it will report its financial results for the second quarter 2025, after the market close on August 12, 2025. Following the release of its financial results, the Company will host a conference call at 4:30 P.M. ET on the same day. Second Quarter 2025 Financial Results Conference CallDate: August 12, 2025Time: 4:30 P.M. ETLive Call: 1-800-274-8461 (U.S. Toll Free) or 1-203-518-9814 (I
First quarter 2025 revenue totaled $2.81 million, an increase of 121%, as compared to $1.27 million for the same period the prior year Gross Profit for the quarter was 42.4%, compared to 12.6% in Q1 2024 and 37.2% in Q4 2024 LANGHORNE, Pa., May 13, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced its first quarter 2025 financial results for the period ending March 31, 2025. First Quarter 2025 Financial Highlights: Net Revenue was $2.81 million, compared to $1.27 million in Q1 2024 and $3.04 million in Q4 2024.Gross Profit
LANGHORNE, Pa., Aug. 05, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced the appointment of Steve Ciardiello, CPA, to its Board of Directors. With more than 25 years of experience as a senior finance executive and current Chief Accounting Officer of Shutterstock, Inc. (NYSE:SSTK), Mr. Ciardiello has a proven track record of financial leadership, strategic execution, and corporate governance in high-growth, publicly traded companies. "Steve's extensive experience, financial leader
LANGHORNE, Pa., Jan. 02, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced the appointment of Joseph F. McGuire as Chief Financial Officer, effective January 1, 2025. Adam E. Drapczuk III, current Chief Financial Officer, will remain with the Company as a consultant. Adam Levy, Chief Executive Officer, stated, "As our business continues to experience high growth, it is imperative we consistently acquire talented and experienced professionals to join our team particularly in operati
LANGHORNE, Pa., Oct. 04, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced the appointment of Kip Crecca to its Scientific Advisory Board. "We are thrilled to appoint Kip to our Scientific Advisory Board. He adds to our team a wealth of knowledge and experience as a top medical device sales professional," said Adam Levy, NEXGEL's CEO. "Mr. Crecca will be invaluable to the Company as we advance our medical device and healthcare programs. He is an important addition to our group of e